Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's Centralized Patient Affairs Office Aims For No Disruption

Executive Summary

New office will develop agency-wide patient engagement policy and serve as entry point for patient groups new to FDA, but will not interfere with existing relationships between advocates and the drugs and biologics centers, FDA Commissioner Gottlieb says.


Related Content

US FDA Is Dedicating A 'Patient Affairs' Staff Without A Formal Reorg
US FDA's Patient Affairs Office Is An Office … In Spirit
Gottlieb Promotes 'Team' Work For Product Reviews
Patient Advocates Continue To Push US FDA For Central Office
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts